68Ga-DOTATATE Uptake in Primary Breast Cancer.

Ga-DOTA peptides have revolutionized the imaging of neuroendocrine tumors because the agents are specific to somatostatin receptors. However, other tumors, including breast cancer, have been shown to express somatostatin receptors. We present the case of a 74-year-old woman with primary cardiac paraganglioma, who was found to have Ga-DOTATATE activity in the breast on staging PET/CT. Subsequent breast imaging workup and biopsy confirmed primary invasive lobular breast cancer, which was not F-FDG-avid on prior FDG PET/CT. Our case is in alignment with prior studies that suggest that Ga-DOTA peptides may play a future role in imaging breast cancer patients.

[1]  E. Ambinder,et al.  Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma , 2020, Radiology case reports.

[2]  D. Borges Faria,et al.  Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor , 2018, Medicine.

[3]  A. G. García Vicente,et al.  18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[4]  M. Funari,et al.  68Ga-DOTATATE PET/CT in Nonneuroendocrine Tumors: A Pictorial Essay. , 2017, Clinical nuclear medicine.

[5]  M. de Jong,et al.  Review: Receptor Targeted Nuclear Imaging of Breast Cancer , 2017, International journal of molecular sciences.

[6]  S. Kurozumi,et al.  Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma. , 2016, Anticancer Research.

[7]  D. Groheux,et al.  18F-FDG PET/CT for Staging and Restaging of Breast Cancer , 2016, The Journal of Nuclear Medicine.

[8]  Ren-Shyan Liu,et al.  Role of 2-[18F] Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in the Post-Therapy Surveillance of Breast Cancer , 2014, PloS one.

[9]  R. Rouzier,et al.  Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. , 2013, Anticancer research.

[10]  W. Moon,et al.  The Role of PET/CT for Evaluating Breast Cancer , 2007, Korean journal of radiology.

[11]  P. Watson,et al.  Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology , 2005, Breast Cancer Research and Treatment.

[12]  E. Krenning,et al.  Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  I. Steffen,et al.  Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours , 2008, Nuklearmedizin.

[14]  J. Laissue,et al.  Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.